• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Magrath George

    3/18/26 4:10:31 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRD alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Magrath George

    (Last)(First)(Middle)
    C/O OPUS GENETICS, INC.
    8 DAVIS DRIVE, SUITE 220

    (Street)
    DURHAM NORTH CAROLINA 27713

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Opus Genetics, Inc. [ IRD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/16/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock03/16/2026S(1)24,438D$5.2102(2)1,750,855D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.
    2. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.21 to $5.215, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    /s/ Amy Rabourn, by Power of Attorney03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $IRD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRD

    DatePrice TargetRatingAnalyst
    3/30/2026$15.00Overweight
    Cantor Fitzgerald
    3/16/2026$10.00Outperform
    Oppenheimer
    1/20/2026$7.00Buy
    BTIG Research
    12/10/2025$9.00Buy
    B. Riley Securities
    11/25/2025$7.00Overweight
    Piper Sandler
    10/29/2025$8.00Outperform
    Wedbush
    10/16/2025$9.00Buy
    Chardan Capital Markets
    4/11/2025$6.00Buy
    Craig Hallum
    More analyst ratings

    $IRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schachle Joseph K

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:12:35 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Zaremba Rabourn Amy

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:11:39 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Magrath George

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    3/18/26 4:10:31 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

    RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz

    3/24/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics to Present at Upcoming Investor Conferences in March 2026

    RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026Time: 3:00 p.m. ETLocation: Miami, FL Citizens Life Sciences Conference Date: Wednesday, March 11, 2026Time: 2:50 p.m. ETLocation: Miami, FL RBC Capital Markets Global Ophthalmology Conference Date: Wednesday, March 25, 2026Time: 11:45 a.m. ETLoc

    3/3/26 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Opus Genetics with a new price target

    Cantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00

    3/30/26 8:19:42 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Opus Genetics with a new price target

    Oppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00

    3/16/26 8:42:37 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Opus Genetics with a new price target

    BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00

    1/20/26 9:23:30 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/31/25 4:33:33 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Magrath George bought $97,600 worth of shares (100,000 units at $0.98), increasing direct ownership by 20% to 599,150 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    12/30/24 4:26:20 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Yerxa Benjamin R bought $9,834 worth of shares (10,000 units at $0.98), increasing direct ownership by 3% to 342,800 units (SEC Form 4)

    4 - Opus Genetics, Inc. (0001228627) (Issuer)

    11/25/24 4:18:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    SEC Filings

    View All

    SEC Form DEF 14A filed by Opus Genetics Inc.

    DEF 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/23/26 4:06:05 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Opus Genetics Inc.

    S-3 - Opus Genetics, Inc. (0001228627) (Filer)

    3/13/26 4:56:07 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Opus Genetics Inc.

    PRE 14A - Opus Genetics, Inc. (0001228627) (Filer)

    3/12/26 4:58:34 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Leadership Updates

    Live Leadership Updates

    View All

    Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

    RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial

    9/2/25 8:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Financials

    Live finance-specific insights

    View All

    Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

    - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or

    3/10/26 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

    Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive three-month data from the pediatric cohort

    9/30/25 7:00:00 AM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

    - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, In

    8/13/25 4:30:00 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Opus Genetics Inc.

    SC 13D - Opus Genetics, Inc. (0001228627) (Subject)

    10/29/24 5:26:27 PM ET
    $IRD
    Biotechnology: Pharmaceutical Preparations
    Health Care